These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 30943990)

  • 21. Healthcare staff's perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study.
    Nordgren J; Monwell B; Johnson B; Gunnarsson NV; Capusan AJ
    Addict Sci Clin Pract; 2024 Apr; 19(1):25. PubMed ID: 38581022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder.
    Brothers TD; Fraser J; MacAdam E; Morgan B; Webster D
    Drug Alcohol Rev; 2022 Feb; 41(2):430-434. PubMed ID: 34347327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
    Soyka M; Groß G
    Am J Drug Alcohol Abuse; 2021 Sep; 47(5):599-604. PubMed ID: 34407703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue.
    Clay S; Treloar C; Degenhardt L; Grebely J; Christmass M; Gough C; Hayllar J; McDonough M; Henderson C; Crawford S; Farrell M; Marshall A
    Int J Drug Policy; 2023 May; 115():104002. PubMed ID: 37003194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in Opioid Agonist Treatment Practice in Germany during the COVID-19 Pandemic: What Have Physicians Done, and What Would They Like to Keep Doing?
    Lehmann K; Kuhn S; Schulte B; Verthein U
    Eur Addict Res; 2023; 29(5):323-332. PubMed ID: 37557092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
    Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
    Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018.
    Krebs E; Homayra F; Min JE; MacDonald S; Gold L; Carter C; Nosyk B
    Drug Alcohol Depend; 2021 Aug; 225():108799. PubMed ID: 34087747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic.
    Mravčík V; Janíková B; Drbohlavová B; Popov P; Pirona A
    Harm Reduct J; 2018 Dec; 15(1):60. PubMed ID: 30514306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New slow-release buprenorphine formulations for optimization of opioid substitution].
    Soyka M; Pogarell O
    Nervenarzt; 2019 Sep; 90(9):932-937. PubMed ID: 31399813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Administration and patient-incurred costs associated with opioid agonist treatment in Norway.
    Pedersen MH; Danø A; Gibbons C; Jensen R
    Curr Med Res Opin; 2022 Nov; 38(11):1959-1965. PubMed ID: 36172758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancing motivation within a rapid opioid substitution treatment feasibility RCT: a nested qualitative study.
    Ayres R; Ingram J; Rees A; Neale J; Beattie A; Telfer M
    Subst Abuse Treat Prev Policy; 2014 Nov; 9():44. PubMed ID: 25407020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
    Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
    BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of heroin abstinence in opiate substitution therapy in heroin-only users and dual users of heroin and crack.
    Heidebrecht F; MacLeod MB; Dawkins L
    Addict Behav; 2018 Feb; 77():210-216. PubMed ID: 29065377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accessing opioid agonist treatment in prison in England and Scotland remains problematic - the views of people with lived experience.
    Webster R; Fearns C; Harriott P; Millar L; Simpson J; Wallace J; Wheatley M
    Int J Prison Health (2024); 2024 May; 20(2):143-155. PubMed ID: 38984599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buprenorphine implants in medical treatment of opioid addiction.
    Chavoustie S; Frost M; Snyder O; Owen J; Darwish M; Dammerman R; Sanjurjo V
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):799-807. PubMed ID: 28571505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed-methods study.
    Allen E; Samadian S; Altobelli G; Johnson J; Holmwood C
    Drug Alcohol Rev; 2023 May; 42(4):791-802. PubMed ID: 36788357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
    Paul LA; Bayoumi AM; Chen C; Kocovska E; Smith BT; Raboud JM; Gomes T; Kendall C; Rosella LC; Bitonti-Bengert L; Rush B; Yu M; Spithoff S; Crichlow F; Wright A; Watford J; Besharah J; Munro C; Taha S; Nosyk B; Strike C; Manson H; Kahan M; Leece P
    Addiction; 2023 Apr; 118(4):686-697. PubMed ID: 36401610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence.
    Ridge G; Gossop M; Lintzeris N; Witton J; Strang J
    J Subst Abuse Treat; 2009 Jul; 37(1):95-100. PubMed ID: 19004598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating the feasibility of prolonged-release buprenorphine formulations as an alternative to daily opioid agonist therapy regardless of prior treatment adherence: a pilot study.
    Hard B; DeSilva M
    Pilot Feasibility Stud; 2023 Jul; 9(1):113. PubMed ID: 37403145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.